Ageing and multiple sclerosis
The factor that is most relevant and strongly associated with the clinical course of multiple
sclerosis is chronological age. Very young patients exclusively have relapsing remitting …
sclerosis is chronological age. Very young patients exclusively have relapsing remitting …
[HTML][HTML] Brain health: time matters in multiple sclerosis
Introduction We present international consensus recommendations for improving diagnosis,
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …
management and treatment access in multiple sclerosis (MS). Our vision is that these will be …
How patients with multiple sclerosis acquire disability
Patients with multiple sclerosis acquire disability either through relapse-associated
worsening (RAW) or progression independent of relapse activity (PIRA). This study …
worsening (RAW) or progression independent of relapse activity (PIRA). This study …
Ponesimod compared with teriflunomide in patients with relapsing multiple sclerosis in the active-comparator phase 3 OPTIMUM study: a randomized clinical trial
Importance To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing
Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease …
Multiple Sclerosis (OPTIMUM) trial is the first phase 3 study comparing 2 oral disease …
Automated brain extraction of multisequence MRI using artificial neural networks
Brain extraction is a critical preprocessing step in the analysis of neuroimaging studies
conducted with magnetic resonance imaging (MRI) and influences the accuracy of …
conducted with magnetic resonance imaging (MRI) and influences the accuracy of …
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
J Kuhle, H Kropshofer, DA Haering, U Kundu… - Neurology, 2019 - AAN Enterprises
Objective To assess the value of blood neurofilament light chain (NfL) as a biomarker of
recent, ongoing, and future disease activity and tissue damage and its utility to monitor …
recent, ongoing, and future disease activity and tissue damage and its utility to monitor …
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial
Background No treatments have been approved for primary progressive multiple sclerosis.
Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is effective in relapse …
Fingolimod, an oral sphingosine 1-phosphate receptor modulator, is effective in relapse …
Association of brain atrophy with disease progression independent of relapse activity in patients with relapsing multiple sclerosis
Importance The mechanisms driving neurodegeneration and brain atrophy in relapsing
multiple sclerosis (RMS) are not completely understood. Objective To determine whether …
multiple sclerosis (RMS) are not completely understood. Objective To determine whether …
Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis
Personalized treatment is ideal for multiple sclerosis (MS) owing to the heterogeneity of
clinical features, but current knowledge gaps, including validation of biomarkers and …
clinical features, but current knowledge gaps, including validation of biomarkers and …
MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice
J Sastre-Garriga, D Pareto, M Battaglini… - Nature Reviews …, 2020 - nature.com
Early evaluation of treatment response and prediction of disease evolution are key issues in
the management of people with multiple sclerosis (MS). In the past 20 years, MRI has …
the management of people with multiple sclerosis (MS). In the past 20 years, MRI has …